Targeted Therapy in Melanoma

In 2013, the document outlined the advancements in targeted therapy for unresectable and metastatic melanoma, particularly the use of BRAF inhibitors like vemurafenib and dabrafenib, which had shown promise but also faced issues with drug resistance. The FDA had approved vemurafenib for stage IV metastatic melanoma, and the document discussed the management of associated skin toxicities. It also reviewed the potential of combination therapy to overcome resistance and the exploration of therapies for other mutations, such as KIT mutations in acral lentiginous and mucosal melanomas, which had a limited response to imatinib mesylate in a phase II trial with 43 patients. The document mentioned the challenges in targeting NRAS mutations due to the activation of various pathways and the investigation of MEK inhibitors for uveal melanomas. Despite the development of PI3K pathway inhibitors, they had not shown as much efficacy as BRAF inhibitors. The document concluded that while targeted therapies have improved outcomes for metastatic melanoma patients, overcoming drug resistance and finding effective treatment combinations remain significant challenges.